MedElevator Войти в исследования
← Поиск публикаций

DOI 10.26355/eurrev_202205_28737

Медицинская библиотека · European review for medical and pharmacological sciences · 2022

Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial.

Nogueira Cleto Dantas, Frota Samuel, Chaves Huylmer Lucena, de Sousa Juliana Cordeiro, Veloso Guilherme de Sousa, Araujo Francisco Jonathan Dos Santos, Silva Gabriel Barbosa, Ferreira Samuel Silva, Alves Marclesson Santos, Nasser Fabio, Rangel Ezequiel, Neto Francisco Martins, Caminha Iusta, Nascimento Ellen, Tavora Fabio

СтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

Standard treatment for chronic obstructive pulmonary disease (COPD) includes inhalation therapy along with mucoactive drugs. The aim of this study was to assess the efficacy and safety of orally administered mucolytic N-acetylcysteine and propolis (NACp) in COPD patients.

PATIENTS AND

METHODS

A randomized, double-blind, prospective, interventional, 6 months study was conducted at the Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia. Effects of daily NACp administration (600 mg, 1200 mg or placebo) on exacerbation, life quality (St. George's Respiratory Questionnaire-SGRQ), symptoms (COPD assessment test-CAT; Visual analogue cough scale-VAS; Leicester Cough Questionnaire-LCQ; Medical Research Council Dyspnoea scale-mMRC) and spirometric parameters in 120 COPD patients were assessed. Tests were conducted at three-time points: baseline, after three months and after 6 months of NACp treatment.

RESULTS

Repeated measures ANOVA showed that pulmonary function parameters, 6-minute walk test and mMRC score did not significantly change during the study. Cough VAS and CAT scores were significantly different between groups as within experimental groups. LCQ and SGRQ scores did not differ between placebo, and both examined groups, but within each examined group statistically significant difference was confirmed in observed parameters during therapy. Factorial analysis and subsequent binary logistic regression revealed "Symptoms related factor" as the strongest predictor of exacerbation for supplemented groups (p<0.01).

CONCLUSIONS

Treatment with high NACp for 6 months is safe and beneficial for cough and expectoration symptoms and improves the life quality. NACp significantly reduces acute exacerbation frequency in COPD patients by controlling COPD related symptoms.

Для цитирования: Nogueira Cleto Dantas, Frota Samuel, Chaves Huylmer Lucena, de Sousa Juliana Cordeiro, Veloso Guilherme de Sousa, Araujo Francisco Jonathan Dos Santos, Silva Gabriel Barbosa, Ferreira Samuel Silva, Alves Marclesson Santos, Nasser Fabio, Rangel Ezequiel, Neto Francisco Martins, Caminha Iusta, Nascimento Ellen, Tavora Fabio. Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD): a randomized, double-blind, placebo-controlled trial.. European review for medical and pharmacological sciences. 2022. DOI: 10.26355/eurrev_202205_28737.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.